Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5852W HIGH $55.90
Volume
7.07 K
Value Traded
148.44 K
Short % Float
0.46%
+33.09%Week
+58.57%1 Month
+90.07%3 Month
-20.7%6 Month
-99.99%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.44 M
EPS (TTM)
-17.54
P/E Ratio
-
Ent. Value
5.61 M
Total Shares
1.03 M
Float Shares
4.74 M
Insiders
0.52%
Institutions
0.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SHPH Catalyst Timeline
Dated clinical, regulatory and corporate events for Shuttle Pharmaceuticals Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Shuttle Pharmaceuticals Holdings, Inc.
130Total events
0Upcoming
13Tier-1 (high impact)
2022 to 2026Coverage
Event history 50
◆Trial CompletionRopidoxuridineTrial
Phase 2 trial expected to complete over 18-24 months
glioblastomasource ↗
▼Equity OfferingCorporate
Public offering of common stock and pre-funded warrants for $3.5 million gross proceeds
◆Trial CompletionRopidoxuridineTrial
Phase 2 trial expected to be completed over 18 to 24 months
glioblastomasource ↗
▲Enrollment UpdateRopidoxuridineTrial
63% enrollment achieved in Phase 2 trial of Ropidoxuridine for glioblastoma
glioblastomasource ↗
▼Reverse Stock SplitCorporate
Board approved proposed 25-for-1 reverse stock split, subject to Nasdaq approval
▲Enrollment UpdateRopidoxuridineTrial
Nearly 50% patient enrollment achieved in initial randomized portion
glioblastomasource ↗
▲Patent GrantedIP / Competition
Filed provisional patent for PSMA-Targeted PARP Inhibitor Conjugates
prostate cancersource ↗
▲Partnership / LicenseCorporate
Sponsored research agreement with UCSF to develop PSMA-targeted ligand
prostate cancersource ↗
▲Enrollment MilestoneRopidoxuridineTrial
Nearly achieved 50% enrollment in initial randomized portion of Phase 2 trial
glioblastomasource ↗
●Composition Patent FiledIP / Competition
Filed provisional patent application for PSMA-targeted PARP inhibitor conjugates
prostate cancersource ↗
▼Equity OfferingCorporate
Pricing of $5.75 million underwritten public offering of common stock and pre-funded warrants
▲Enrollment UpdateRopidoxuridineTrial
40% enrollment in initial randomized portion of Phase 2 trial; 16 of 40 patients enrolled
glioblastomasource ↗
▲Partnership / LicenseCorporate
Sponsored research agreement with UCSF to advance pre-clinical development of PSMA ligand
prostate cancersource ↗
▲Enrollment MilestoneRopidoxuridineTrial
25% enrollment achieved in initial randomized portion of Phase 2 trial
glioblastomasource ↗
◆Oral PresentationPresentation
CEO participation in Lytham Partners 2025 Investor Healthcare Summit fireside chat
▲Partnership / LicenseCorporate
Sponsored research agreement with UCSF to advance PSMA-B ligand preclinical development
prostate cancersource ↗
▲Patent GrantedIP / Competition
Patent application filed for PSMA-B intellectual property
prostate cancersource ↗
▲First Patient DosedRopidoxuridineTrial
First patient dosed at UVA Cancer Center in Phase 2 trial of Ropidoxuridine for glioblastoma
glioblastomasource ↗
▲Enrollment UpdateRopidoxuridineTrial
Expanded patient enrollment to include UVA Cancer Center as second site
glioblastomasource ↗
◆Enrollment UpdateRopidoxuridineTrial
Additional patients undergoing screening for enrollment
glioblastomasource ↗
▼Debt Royalty FinancingCorporate
Closed convertible note and warrant offering for $790,000 gross proceeds
▲First Patient DosedRopidoxuridineTrial
First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma
glioblastomasource ↗
●IND Enabling CompleteRopidoxuridinePreclinical
Proceeds to fund IND-enabling and Phase I/II trials for Ropidoxuridine
cancer (radiation sensitizer)source ↗
▲Trial InitiationTrial
Phase 2 clinical trial began enrolling patients with IDH wild-type, methylation negative glioblastoma
glioblastomasource ↗
▲Enrollment MilestoneTrial
Entered into agreements with six trial sites, five fully prepared to begin treating patients
glioblastomasource ↗
▲Enrollment CompleteRopidoxuridineTrial
Completed clinical trial site enrollment for Phase 2 of Ropidoxuridine
glioblastomasource ↗
▼Equity OfferingCorporate
Closed convertible note and warrant offering for $790,000 gross proceeds
▲First Patient DosedRopidoxuridineTrial
First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma
glioblastomasource ↗
Past FDA Catalysts and PDUFA Decisions
How SHPH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SHPH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HRT FINANCIAL LP10% Owner | Sell | -82,116 | $4.48 | 07/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SHPH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SHPH for Q2 2026. | ||||
SHPH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SHPH ranks across every disease it competes in
Competitive Position is a premium feature
See how SHPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSHPH News
SHPH▼ -5.1%on this news
Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
Shuttle Pharmaceuticals Holdings, Inc. has announced that it is not in compliance with NASDAQ's periodic filing requirements due to its failure to submit its Quarterly Report. This noncompliance is based on the Nasdaq Listing Rule 5250(c)(1). The situation poses a risk to the company's continued listing on the exchange.
Read more →SHPH▲ +6.3%on this news
United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site
United Dogecoin Inc., recently acquired by Shuttle Pharmaceutical Holdings, aims to become the largest Dogecoin miner by hashrate. The company has purchased ElphaPex DG1+ mining units and secured a renewable energy site. Operations are expected to commence in about 60 days, leveraging low-cost hydroelectric power for efficiency.
Read more →SHPH▲ +6.3%on this newsshared move
United Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting
United Dogecoin has initiated a strategy to enhance its digital infrastructure, focusing on data centers and power generation to support DOGE mining and AI workloads. The company is exploring opportunities in Idaho and Alberta, citing favorable conditions for digital asset mining. This initiative aims to create additional revenue streams and improve operational efficiencies in a competitive market.
Read more →SHPH▼ -6.5%on this news· ran to -19% by day 3
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time
Shuttle Pharmaceuticals Holdings, Inc. has announced a 10-for-1 reverse stock split effective June 11, 2026. This move aims to reduce the number of outstanding shares from approximately 6.37 million to about 637,108 shares. The split is part of the company's strategy to comply with Nasdaq's listing requirements and enhance its long-term capital structure.
Read more →SHPHShuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
Shuttle Pharmaceuticals has finalized its merger with United Dogecoin and confirmed a purchase order for up to 3,000 ElphaPex mining rigs. The rigs will be used for mining Dogecoin and Litecoin, aiming to accumulate these cryptocurrencies as long-term assets. The deployment of the mining fleet is expected to begin within 60 days, enhancing Shuttle's position in the cryptocurrency mining sector.
Read more →SHPH▼ -32.8%on this news
United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation
Shuttle Pharmaceutical Holdings, Inc. has announced a merger with United Dogecoin Inc., aiming to create the largest publicly listed Dogecoin mining company. The merger, supported by an $11 million PIPE financing, will enhance United Dogecoin's mining capacity and operational efficiency. The leadership team, led by CEO Ryan Trasolini, aims to leverage their expertise to establish a strong market position in Dogecoin mining.
Read more →SHPH▼ -32.8%on this newsshared move
Shuttle Merges with United Dogecoin to Become the World’s Largest Public Dogecoin Miner
Shuttle Pharmaceutical Holdings, Inc. has announced a merger with United Dogecoin, aiming to create the largest publicly listed Dogecoin mining company. The merger includes an $11 million PIPE financing and is expected to enhance mining capacity significantly. United Dogecoin's leadership has a strong background in cryptocurrency, positioning the combined entity for growth despite inherent market risks.
Read more →SHPHShuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percenta
Shuttle Pharmaceutical Holdings, Inc. has announced a definitive merger agreement with United Dogecoin Inc. to establish the largest publicly listed Dogecoin mining company. The deal is supported by an $11 million PIPE financing expected to close shortly. The combined entity will leverage United Dogecoin's competitive advantages, including access to new high-efficiency mining rigs and renewable energy sources. Despite the promising outlook, the merger is contingent upon stockholder approval, and the success of its planned mining strategy in the competitive cryptocurrency market will need to be demonstrated.
Read more →SHPH▼ -22.9%on this news· ran to -38% by day 1
RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows
Shuttle Pharmaceuticals has launched an upgraded version of its molecule.ai platform, enhancing its capabilities in therapeutic discovery through advanced AI models. This update allows for better evaluation and prioritization of therapeutic candidates, facilitating faster decision-making. The introduction of an autonomous AI agent system aims to streamline complex scientific workflows, potentially reducing costs and timelines in drug development.
Read more →SHPH▲ +5.6%on this news
Shuttle Pharmaceuticals Announces $3.5 Million Public Offering
Shuttle Pharmaceuticals has announced a public offering to raise approximately $3.5 million through the sale of common stock and warrants. The company plans to use part of the proceeds for marketing and general corporate purposes. The offering is expected to close around March 9, 2026, pending customary conditions.
Read more →SHPH▲ +6.3%on this news· ran to +50% by day 3
Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs – and Why Molecule.ai’s Drug Discovery Platform Matters More Than Ever
Shuttle Pharmaceuticals applauds Utah for becoming the first state to allow AI systems to authorize prescription refills without direct physician involvement. This initiative aims to reduce healthcare costs and improve access, particularly in rural areas. Shuttle's Molecule.ai platform seeks to automate drug discovery processes, minimizing inefficiencies and costs while ensuring safety and oversight. The pilot program may influence future AI regulations in healthcare.
Read more →SHPH▼ -22.3%on this news· ran to -34% by day 3
Shuttle Pharmaceuticals Acquires AI Health Platform
Shuttle Pharmaceuticals has acquired Molecule.ai, a Canadian AI company, for $8 million, with potential additional payments based on performance milestones. This acquisition aims to enhance Shuttle's drug discovery capabilities and advance its mission in precision radiotherapy. Both companies express optimism about the collaboration's potential impact on drug development.
Read more →SHPHShuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00
Shuttle Pharmaceuticals Holdings, Inc. announced a private placement agreement to raise approximately $2.5 million, with shares priced at $4.00 each, above the market rate. The funds will be allocated for marketing and general corporate purposes. The offering is expected to close soon, pending customary conditions.
Read more →SHPH▼ -7.2%on this news
Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform
Shuttle Pharmaceuticals Holdings, Inc. has announced a binding term sheet to acquire the assets of Canadian AI company Molecule for $10 million. This acquisition aims to enhance Shuttle's capabilities in molecular modeling and predictive analytics, crucial for advancing their precision radiotherapy solutions. The deal will involve a mix of cash and stock, contingent on performance milestones.
Read more →SHPHShuttle Executes LOI with Molecule.ai
Shuttle Pharmaceuticals has signed a non-binding letter of intent to acquire Molecule.ai, an AI-driven company focused on drug discovery. The acquisition aims to leverage Molecule.ai's advanced machine learning models to enhance the efficiency and accuracy of therapeutic development. Shuttle will pay $10 million, contingent on achieving certain milestones. This partnership is expected to significantly improve drug discovery timelines and outcomes.
Read more →SHPH▼ -13.9%on this newsshared move
Shuttle to Enter $3.24 Billion AI Pharmaceutical Market
Shuttle Pharmaceuticals Holdings, Inc. has announced a non-binding letter of intent to acquire Molecule.ai, an AI company focused on drug discovery. This acquisition aims to leverage advanced machine learning models to enhance the efficiency and accuracy of therapeutic development. The deal is valued at $10 million, contingent on achieving specific milestones.
Read more →SHPH▼ -5.1%on this news
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
Shuttle Pharmaceuticals has reported significant progress in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma, achieving 63% enrollment. The treatment has been well-tolerated, with 72% of patients completing all cycles. The company aims to complete enrollment by the end of the year, with data readouts expected in 2026.
Read more →SHPHShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
Shuttle Pharmaceuticals has successfully closed a private placement, raising $4.25 million through the issuance of shares priced at $3.60 each. The funds are intended for potential acquisitions, marketing, and general corporate purposes. The company aims to enhance cancer treatment outcomes through its innovative therapies designed to improve radiation therapy effectiveness.
Read more →SHPHShuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
Shuttle Pharmaceuticals announced a private placement agreement to raise $4.25 million through the issuance of shares priced at $3.60 each. The company plans to use the proceeds for acquisitions, marketing, and other corporate purposes. The offering is expected to close around June 23, 2025, pending customary conditions. WestPark Capital is the exclusive placement agent for this transaction.
Read more →About Shuttle Pharmaceuticals Holdings, Inc.
Headquarters401 PROFESSIONAL DRIVE, GAITHERSBURG, MD, 20879
BIOPHARMAWATCH ELITE PLUS
Trade the next SHPH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime